PTEN公司
PI3K/AKT/mTOR通路
癌症研究
蛋白激酶B
白血病
生物
小RNA
细胞凋亡
细胞生长
抑制器
信号转导
细胞生物学
免疫学
基因
遗传学
作者
Tian Yuan,Lei Zhao,J Chen,Weijia Li,Wei Li,Qi Zhang,Yingchang Mi,Rashmi S. Goswami,Jihui You,Daniel Lin,Ming Qian,Steliana Calin,Yanchao Liang,Roberto N. Miranda,George A. Călin,Xin Zhou,Li Ma,Patrick A. Zweidler‐McKay,Bing Liu,Andrew P. Weng,L. Jeffrey Medeiros,Yujie Zhang,M. James You
出处
期刊:Leukemia
[Springer Nature]
日期:2017-03-10
卷期号:31 (11): 2355-2364
被引量:54
摘要
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy, and T-ALL patients are prone to early disease relapse and suffer from poor outcomes. The PTEN, PI3K/AKT and Notch pathways are frequently altered in T-ALL. PTEN is a tumor suppressor that inactivates the PI3K pathway. We profiled miRNAs in Pten-deficient mouse T-ALL and identified miR-26b as a potentially dysregulated gene. We validated decreased expression levels of miR-26b in mouse and human T-ALL cells. In addition, expression of exogenous miR-26b reduced proliferation and promoted apoptosis of T-ALL cells in vitro, and hindered progression of T-ALL in vivo. Furthermore, miR-26b inhibited the PI3K/AKT pathway by directly targeting PIK3CD, the gene encoding PI3Kδ, in human T-ALL cell lines. ShRNA for PIK3CD and CAL-101, a PIK3CD inhibitor, reduced the growth and increased apoptosis of T-ALL cells. Finally, we showed that PTEN induced miR-26b expression by regulating the differential expression of Ikaros isoforms that are transcriptional regulators of miR-26b. These results suggest that miR-26b functions as a tumor suppressor in the development of T-ALL. Further characterization of targets and regulators of miR-26b may be promising for the development of novel therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI